JP2014506231A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014506231A5 JP2014506231A5 JP2013530249A JP2013530249A JP2014506231A5 JP 2014506231 A5 JP2014506231 A5 JP 2014506231A5 JP 2013530249 A JP2013530249 A JP 2013530249A JP 2013530249 A JP2013530249 A JP 2013530249A JP 2014506231 A5 JP2014506231 A5 JP 2014506231A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- protein
- composition according
- smad7
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (17)
- 組換えSmad7（mothers against decapentaplegic homolog 7）タンパク質または該組換えSmad7タンパク質をコードする組換え核酸を含み、該Smad7タンパク質がタンパク質導入ドメイン(PTD)と融合しており、かつ核に移行する、炎症状態を処置または予防するための医薬の調製において使用するための組成物。
- 前記組換え核酸が、Smad7タンパク質をコードする発現ベクターである、請求項1記載の組成物。
- 前記組換え核酸が、活性化因子の非存在下でSmad7の発現を妨げる調節ドメインを含む、請求項1または2記載の組成物。
- 前記発現ベクターがウイルスベクターである、請求項2記載の組成物。
- 前記発現ベクターが非ウイルスベクターである、請求項2記載の組成物。
- 前記PTDがTatである、請求項1記載の組成物。
- 前記医薬が、パッチ、ゲル状組成物、マイクロスフェア、マイクロビーズ、またはそれらの組み合わせに製剤化されている、請求項1〜6のいずれか一項記載の組成物。
- 前記医薬が全身投与用に製剤化されている、請求項1〜6のいずれか一項記載の組成物。
- 前記炎症状態が、腸管粘膜炎、口腔粘膜炎、乾癬、自己免疫疾患、急性創傷、慢性創傷、潰瘍、外傷、手術、化学療法、放射線療法、またはサイトカイン療法より選択される、請求項1〜6および8のいずれか一項記載の組成物。
- 前記医薬が局所投与用に製剤化されている、請求項1〜6のいずれか一項記載の組成物。
- 前記炎症状態が口腔粘膜炎である、請求項1〜8のいずれか一項記載の組成物。
- 前記炎症状態が癌に関連し、該癌が、口腔癌、結腸癌、乳癌、頭頸部癌、膵臓癌、および上半身への放射線照射または反復化学療法により処置されるその他の癌からなる群より選択される、請求項1〜8のいずれか一項記載の組成物。
- タンパク質導入ドメイン(PTD)に融合されているSmad7タンパク質を含み、該Smad7タンパク質が核に移行する、組成物。
- 前記PTDがTatである、請求項13記載の組成物。
- 1つまたは複数の薬学的に許容される賦形剤と共に製剤化されている、請求項13または14記載の組成物。
- 前記1つまたは複数の薬学的に許容される賦形剤が局所投与用に選択される、請求項15記載の組成物。
- 前記1つまたは複数の薬学的に許容される賦形剤が全身投与用に選択される、請求項15記載の組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38544510P | 2010-09-22 | 2010-09-22 | |
| US61/385,445 | 2010-09-22 | ||
| PCT/US2011/052499 WO2012040295A2 (en) | 2010-09-22 | 2011-09-21 | Therapeutic applications of smad7 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014506231A JP2014506231A (ja) | 2014-03-13 |
| JP2014506231A5 true JP2014506231A5 (ja) | 2014-11-13 |
| JP6124791B2 JP6124791B2 (ja) | 2017-05-10 |
Family
ID=45874343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530249A Active JP6124791B2 (ja) | 2010-09-22 | 2011-09-21 | Ｓｍａｄ７の治療的適用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9084746B2 (ja) |
| EP (2) | EP2618829B1 (ja) |
| JP (1) | JP6124791B2 (ja) |
| CN (2) | CN105457016B (ja) |
| CA (1) | CA2849382C (ja) |
| HK (1) | HK1223294A1 (ja) |
| IL (1) | IL225406B (ja) |
| WO (1) | WO2012040295A2 (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105457016B (zh) | 2010-09-22 | 2022-06-24 | 科罗拉多大学董事会 | Smad7的治疗应用 |
| CA2904329C (en) | 2013-03-08 | 2021-11-30 | The Regents Of The University Of Colorado, A Body Corporate | Ptd-smad7 therapeutics |
| KR20180002706A (ko) * | 2015-04-23 | 2018-01-08 | 워싱턴 스테이트 유니버시티 | Smad7 유전자 전달 치료법 |
| KR101853923B1 (ko) * | 2016-01-25 | 2018-05-02 | 연세대학교 산학협력단 | Smad 단백질을 포함하는 자가 면역 질환 치료용 조성물, Smad 단백질을 포함하는 융합 단백질, 이를 제조하기 위한 벡터, 및 이의 제조 방법 |
| US10772813B2 (en) | 2016-06-03 | 2020-09-15 | Colradel, LLC | Compositions and methods of administering a colchicine based topical composition for the prevention of radiation fibrosis |
| CN112004546A (zh) * | 2017-12-30 | 2020-11-27 | 科罗拉多大学董事会 | Ptd-smad7融合蛋白治疗剂 |
| WO2019133950A1 (en) * | 2017-12-30 | 2019-07-04 | The Regents Of The University Of Colorado, A Body Corporate | Smad7 for treatment and prevention of posterior capsule opacification |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8200523A (nl) | 1982-02-11 | 1983-09-01 | Univ Leiden | Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna. |
| US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US4952500A (en) | 1988-02-01 | 1990-08-28 | University Of Georgia Research Foundation, Inc. | Cloning systems for Rhodococcus and related bacteria |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5302523A (en) | 1989-06-21 | 1994-04-12 | Zeneca Limited | Transformation of plant cells |
| US5550318A (en) | 1990-04-17 | 1996-08-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US7705215B1 (en) | 1990-04-17 | 2010-04-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US5322783A (en) | 1989-10-17 | 1994-06-21 | Pioneer Hi-Bred International, Inc. | Soybean transformation by microparticle bombardment |
| AU658818B2 (en) * | 1989-12-21 | 1995-05-04 | Johns Hopkins University School Of Medicine, The | Method of delivering molecules into eukaryotic cells using tat protein conjugate |
| US5484956A (en) | 1990-01-22 | 1996-01-16 | Dekalb Genetics Corporation | Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| US5610042A (en) | 1991-10-07 | 1997-03-11 | Ciba-Geigy Corporation | Methods for stable transformation of wheat |
| US5702932A (en) | 1992-07-20 | 1997-12-30 | University Of Florida | Microinjection methods to transform arthropods with exogenous DNA |
| EP0652965A1 (en) | 1992-07-27 | 1995-05-17 | Pioneer Hi-Bred International, Inc. | An improved method of agrobacterium-mediated transformation of cultured soybean cells |
| EP0656950B1 (en) * | 1992-08-21 | 1998-11-04 | Biogen, Inc. | Tat-derived transport polypeptides |
| GB9222888D0 (en) | 1992-10-30 | 1992-12-16 | British Tech Group | Tomography |
| US5436222A (en) | 1993-03-15 | 1995-07-25 | The Research Foundation Of State University Of New York | Use of platelet factor 4 to treat inflammatory diseases |
| US5656610A (en) | 1994-06-21 | 1997-08-12 | University Of Southern California | Producing a protein in a mammal by injection of a DNA-sequence into the tongue |
| US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
| US5945100A (en) | 1996-07-31 | 1999-08-31 | Fbp Corporation | Tumor delivery vehicles |
| US5981274A (en) | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
| GB2320431B (en) | 1996-12-20 | 2000-08-30 | Johnson & Johnson Medical | Compositions for the treatment of chronic wounds |
| AU747576B2 (en) | 1997-05-20 | 2002-05-16 | Ludwig Institute For Cancer Research | Smad7 and uses thereof |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US5994624A (en) | 1997-10-20 | 1999-11-30 | Cotton Incorporated | In planta method for the production of transgenic plants |
| JP2002509711A (ja) * | 1998-03-27 | 2002-04-02 | イーライ・リリー・アンド・カンパニー | 血管疾患の処置および阻止 |
| US8466134B1 (en) | 1998-06-26 | 2013-06-18 | Athena Neurosciences, Inc. | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| US6998240B2 (en) * | 2001-06-11 | 2006-02-14 | Wisconsin Alumni Research Foundation | Screen for selective inhibitors or activators of Smad protein function |
| AUPR638101A0 (en) * | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
| WO2004022142A1 (en) | 2002-09-06 | 2004-03-18 | 3M Innovative Properties Company | Metering valve for a metered dose inhaler providing consistent delivery |
| KR100472938B1 (ko) * | 2002-10-31 | 2005-03-11 | 학교법인 한림대학교 | 세포침투 효율을 향상시킨 수송도메인-목표단백질-수송도메인 융합단백질 및 그 용도 |
| NZ547105A (en) * | 2003-10-16 | 2009-02-28 | Univ Edinburgh | Control of ES cell self-renewal and lineage specification, and medium therefor |
| ES2458992T3 (es) * | 2005-01-14 | 2014-05-07 | Camurus Ab | Formulaciones de análogos de GnRH |
| EP1866419A2 (en) | 2005-04-05 | 2007-12-19 | Pioneer-Hi-Bred International, Inc. | Methods and compositions for designing nucleic acid molecules for polypeptide expression in plants using plant virus codon-bias |
| CA2949643C (en) * | 2005-09-27 | 2018-05-15 | Tissuetech, Inc. | Amniotic membrane preparations and purified compositions and methods of use |
| WO2008105925A2 (en) | 2006-09-01 | 2008-09-04 | Oregon Health & Science University | COMPOUNDS AND METHODS FOR MODULATING β-CATENIN/SMAD-7 INTERACTIONS |
| US20080114287A1 (en) * | 2006-11-14 | 2008-05-15 | Kar Neng Lai | Ultrasound Microbubble Mediated Genes Delivery System |
| SG10201607710UA (en) * | 2008-03-17 | 2016-11-29 | Scripps Research Inst | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
| US8591961B2 (en) * | 2008-09-04 | 2013-11-26 | Allergan, Inc. | Aesthetic treatment of scars and aging skin |
| WO2009151600A2 (en) * | 2008-06-10 | 2009-12-17 | Tufts University | Smad proteins control drosha-mediated mirna maturation |
| US20100184033A1 (en) * | 2008-07-16 | 2010-07-22 | West Michael D | Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby |
| CN105457016B (zh) | 2010-09-22 | 2022-06-24 | 科罗拉多大学董事会 | Smad7的治疗应用 |
| EP2833923A4 (en) | 2012-04-02 | 2016-02-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS |
| CA2904329C (en) | 2013-03-08 | 2021-11-30 | The Regents Of The University Of Colorado, A Body Corporate | Ptd-smad7 therapeutics |
-
2011
- 2011-09-21 CN CN201510882397.6A patent/CN105457016B/zh active Active
- 2011-09-21 US US13/822,173 patent/US9084746B2/en active Active
- 2011-09-21 CA CA2849382A patent/CA2849382C/en active Active
- 2011-09-21 CN CN201180051033.3A patent/CN103501803B/zh active Active
- 2011-09-21 JP JP2013530249A patent/JP6124791B2/ja active Active
- 2011-09-21 EP EP11827421.6A patent/EP2618829B1/en active Active
- 2011-09-21 EP EP19167590.9A patent/EP3536337A1/en active Pending
- 2011-09-21 WO PCT/US2011/052499 patent/WO2012040295A2/en active Application Filing
-
2013
- 2013-03-21 IL IL225406A patent/IL225406B/en active IP Right Grant
-
2015
- 2015-06-25 US US14/750,557 patent/US9474784B2/en active Active
-
2016
- 2016-09-30 US US15/282,022 patent/US10350265B2/en active Active
- 2016-10-06 HK HK16111637.8A patent/HK1223294A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014506231A5 (ja) | ||
| Zhu et al. | Janus kinase inhibition ameliorates ischemic stroke injury and neuroinflammation through reducing NLRP3 inflammasome activation via JAK2/STAT3 pathway inhibition | |
| Hua et al. | Tumors vs. chronic wounds: an immune cell's perspective | |
| Gu et al. | Roles of toll-like receptors: From inflammation to lung cancer progression | |
| Bruno et al. | Orchestration of angiogenesis by immune cells | |
| JP2013067645A5 (ja) | ||
| NZ707328A (en) | Virus-containing formulation and use thereof | |
| JP2016517888A5 (ja) | ||
| BRPI0516557A (pt) | pi3 cinases | |
| MY162324A (en) | Immunomodulatory polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections | |
| JP2012515213A5 (ja) | ||
| WO2016210376A3 (en) | Therapeutic peptides and methods of use thereof | |
| Rascoe et al. | Molecular pathogenesis of malignant mesothelioma | |
| Jin et al. | The effect of biodegradable gelatin microspheres on the neuroprotective effects of high mobility group box 1 A box in the postischemic brain | |
| Li et al. | Diazepam inhibited lipopolysaccharide (LPS)-induced pyroptotic cell death and alleviated pulmonary fibrosis in mice by specifically activating GABAA receptor α4-subunit | |
| Devaraja | Current prospects of molecular therapeutics in head and neck squamous cell carcinoma | |
| Jin et al. | MiR-136 controls neurocytes apoptosis by regulating Tissue Inhibitor of Metalloproteinases-3 in spinal cord ischemic injury | |
| JP2021504404A5 (ja) | ||
| EP3030573A1 (en) | Molecular targets for the prevention and/or treatment of fibrosis, hypertrophic scars or keloids | |
| HRP20161147T1 (hr) | Farmaceutski sastav i postupak njegove proizvodnje | |
| JP2013511975A5 (ja) | ||
| JP2017519763A5 (ja) | ||
| JP2016510596A5 (ja) | ||
| Ramadhani et al. | Anthocyanin, tartaric acid, ascorbic acid of roselle flower (Hibiscus sabdariffa L.) for immunomodulatory adjuvant therapy in oral manifestation coronavirus disease-19: An immunoinformatic approach | |
| WO2016122806A8 (en) | Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life |